Astria Therapeutics ATXS Stock
Astria Therapeutics Price Chart
Astria Therapeutics ATXS Financial and Trading Overview
| Astria Therapeutics stock price | 12.58 USD |
| Previous Close | 0 USD |
| Open | 0 USD |
| Bid | 8.95 USD x 200 |
| Ask | 16 USD x 200 |
| Day's Range | 12.45 - 12.59 USD |
| 52 Week Range | 3.56 - 13.29 USD |
| Volume | 0 USD |
| Avg. Volume | 1.09M USD |
| Market Cap | 718.13M USD |
| Beta (5Y Monthly) | 0.019 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13 USD |
ATXS Valuation Measures
| Enterprise Value | 590.19M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.285714 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1017.1775 |
| Price/Book (mrq) | 5.1472993 |
| Enterprise Value/Revenue | 835.962 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Astria Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.019 |
| 52-Week Change | 69.31% |
| S&P500 52-Week Change | 12.81% |
| 52 Week High | 13.29 USD |
| 52 Week Low | 3.56 USD |
| 50-Day Moving Average | 12.77 USD |
| 200-Day Moving Average | 8.52 USD |
ATXS Share Statistics
| Avg. Volume (3 month) | 1.09M USD |
| Avg. Daily Volume (10-Days) | 1.09M USD |
| Shares Outstanding | 57.08M |
| Float | 39.18M |
| Short Ratio | 4.7 |
| % Held by Insiders | 0.48% |
| % Held by Institutions | 94.89% |
| Shares Short | 5.75M |
| Short % of Float | 12.65% |
| Short % of Shares Outstanding | 10.08% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | NaN |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:6 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | September 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -4830.59% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.93% |
| Return on Equity (ttm) | -43.14% |
Income Statement
| Revenue (ttm) | 706K USD |
| Revenue Per Share (ttm) | 0.01 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 706K USD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -124030000 USD |
| Diluted EPS (ttm) | -2.14 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 227.72M USD |
| Total Cash Per Share (mrq) | 3.99 USD |
| Total Debt (mrq) | 4.46M USD |
| Total Debt/Equity (mrq) | 1.91 USD |
| Current Ratio (mrq) | 10.781 |
| Book Value Per Share (mrq) | 2.444 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -119733000 USD |
| Levered Free Cash Flow (ttm) | -80486752 USD |
Profile of Astria Therapeutics
| Country | United States |
| State | MA |
| City | Boston |
| Address | 22 Boston Wharf Road |
| ZIP | 02210 |
| Phone | 617 349 1971 |
| Website | https://www.astriatx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 78 |
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. As of January 23, 2026, Astria Therapeutics, Inc. operates as a subsidiary of BioCryst Pharmaceuticals, Inc.
Q&A For Astria Therapeutics Stock
What is a current ATXS stock price?
Astria Therapeutics ATXS stock price today per share is 12.58 USD.
How to purchase Astria Therapeutics stock?
You can buy ATXS shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Astria Therapeutics?
The stock symbol or ticker of Astria Therapeutics is ATXS.
Which industry does the Astria Therapeutics company belong to?
The Astria Therapeutics industry is Biotechnology.
How many shares does Astria Therapeutics have in circulation?
The max supply of Astria Therapeutics shares is 57.08M.
What is Astria Therapeutics Price to Earnings Ratio (PE Ratio)?
Astria Therapeutics PE Ratio is 0.00000000 now.
What was Astria Therapeutics earnings per share over the trailing 12 months (TTM)?
Astria Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Astria Therapeutics company belong to?
The Astria Therapeutics sector is Healthcare.
Astria Therapeutics ATXS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.85B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.85B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2310.38 USD — |
-1.07
|
— — | 2287.99 USD — | 2333.46 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}